Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure:
or having the structure:
as defined herein.
Pharmaceutical preparation comprising an active dispersed on a matrix
申请人:——
公开号:US20040058896A1
公开(公告)日:2004-03-25
The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.
[EN] IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION<br/>[FR] DERIVES D'IMIDAZO PYRIDINE QUI INHIBENT LA SECRETION D'ACIDE GASTRIQUE
申请人:ASTRA AB
公开号:WO1999055706A1
公开(公告)日:1999-11-04
The present invention relates to imidazo pyridine derivatives of formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxyamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
Process for Preparing a Substituted Imidazopyridine Compound
申请人:Elman Bjorn
公开号:US20090247755A1
公开(公告)日:2009-10-01
The present invention provides a new process for large-scale preparation of substituted imidazopyridine compound of formula (I) wherein R
1
is C
1
-C
6
alkoxy or NH
2
group, comprising the step of reacting a compound of formula (2) with a 3-halo-2-butanone compound in cyclohexanone.
Imidazo pyridine derivatives which inhibit gastric acid secretion
申请人:AstraZeneca AB
公开号:US06313137B1
公开(公告)日:2001-11-06
The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.